Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors.
Jeffrey I WeitzZoltán SzekaneczChristina Charles-SchoemanIvana VranicBurak SahinSara A PacigaZhenyu WangCraig HydeDavid A MartinPublished in: RMD open (2022)
NCT02092467; ClinicalTrials.gov.